Efficacy of a novel fenugreek seed extract (Trigonella foenum-graecum, furocyst™) in polycystic ovary syndrome (PCOS)

International Journal of Medical Sciences

Volumn 12, Issue 10, 2015, Pages 825-831

  Swaroop, Anand ^a   Jaipuriar, Amrita Sarkari ^b   Gupta, Sushil Kumar ^c   Bagchi, Manashi ^a   Kumar, Pawan ^d   Preuss, Harry G ^e   Bagchi, Debasis ^a,f  

^a Cepham Inc   (United States)

^b Jaipuriar Cardiac Center and Garg Hospital   (India)

^c Hormone and Maternity Clinic   (India)

^d Chemical Resources   (India)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF HOUSTON   (United States)

Author keywords

Cyst size; Female subjects; Fenugreek seed extract (Furocyst); Luteinizing (LH) and follicular stimulating hormone (FSH); Polycystic ovary syndrome (PCOS); Safety

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATINE KINASE; FENUGREEK EXTRACT; FOLLITROPIN RELEASING FACTOR; LUTEINIZING HORMONE; UREA; FENUGREEK SEED MEAL; FOLLITROPIN; HEMOGLOBIN; PLANT EXTRACT;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG CAPSULE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; ENZYME BLOOD LEVEL; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MENSTRUAL CYCLE; MULTICENTER STUDY; ORGAN SIZE; OVARY; OVARY POLYCYSTIC DISEASE; PLANT SEED; PREGNANCY; PREMENOPAUSE; TUMOR VOLUME; UREA NITROGEN BLOOD LEVEL; ADOLESCENT; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; LEUKOCYTE COUNT; MIDDLE AGED; PHYTOTHERAPY; POLYCYSTIC OVARY SYNDROME; RANDOMIZED CONTROLLED TRIAL; TRIGONELLA; YOUNG ADULT;

ADOLESCENT; ADULT; FEMALE; FOLLICLE STIMULATING HORMONE; HEMOGLOBINS; HUMANS; LEUKOCYTE COUNT; LUTEINIZING HORMONE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; POLYCYSTIC OVARY SYNDROME; TRIGONELLA; YOUNG ADULT;

EID: 84943268675     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.13024     Document Type: Article

References (29)

1. [Internet] Eisenberg E. Polycystic ovary syndrome (PCOS) fact sheet. http://www.womenshealth.gov/publications/our-publications/fact-sheet/polycystic-ovary-syndrome.html December 23, 2014.
2. Palomba S, Santagni S, Falbo A, et al. Complications and challenges associated with polycystic ovary syndrome: Current perspectives. Int J Women’s Health. 2015; 7:745-63.
3. Obermayer-Pietsch B, Trummer C, Schwetz V, et al. Genetics of insulin resistance in polycystic ovary syndrome. Curr Opin Clin Nutr Metab Care. 2015; 18(4):401-6.
4. Rocca ML, Venturella R, Mocciaro R, et al. Polycystic ovary syndrome: chemical pharmacotherapy. Expert Opin Pharmacother. 2015; 16(9):1369-93.
5. Blank SK, Helm KD, McCartney CR, et al. Polycystic ovary syndrome in adolescence. Ann N Y Acad Sci. 2008; 1135:76-84.
6. Ghaneei A, Jowkar A, Hasani Ghavam MR, et al. Cabergoline plus metformin therapy effects on menstrual irregularity and androgen system in polycystic ovary syndrome women with hyperprolactinemia. Iran J Reprod Med. 2015; 13(2):93-100.
7. Cahill DJ, O’Brien K. Polycystic ovary syndrome (PCOS): Metformin. BMJ Clin Evid. 2015: 1408.
8. Franik S, Kremer JA, Nelen WL, et al. Aromatase inhibitors for subfertile women with polycystic ovary syndrome; summary of a Cochrane review. Fertil Steril. 2015; 103(2): 353-5.
9. Caserta D, Ralli E, Matteucci E, et al. Combined oral contraceptives: health benefits beyond contraception. Panminerva Med. 2014; 56(3):233-44.
10. Dinicola S, Chiuu TT, Unfer V, et al. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome. J Clin Pharmacol. 2014; 54(10):1079-92.
11. De Leo V, Fruzzetti F, Musacchio MC, Scolaro V, Di Sabatino A, Morgante G. Effect of a new oral contraceptive with estradiol valerate/dienogest on carbohydrate metabolism. Contraception 2013;88(3):364-8.
12. Sandeep PM, Boyee TF, Sreejith K. Anti-Androgenic Activity of Nardostachys jatamansi DC and Tribulus terrestris L. and Their Beneficial Effects on Polycystic Ovary Syndrome-Induced Rat Models. Metab Syndr Relat Disord. 2015; 13(6):248-54.
13. Sadrefozalayi S, Farokhi F. Effect of the aqueous extract of Foeniculum vulgure (fennel) on the kidney in experimental PCOS female rats. Avicenna J Phytomed. 2014; 4(2):110-7.
14. Kort DH, Lobo RA. Preliminary evidence that cinnamon improves menstrual cyclicity in women with polycystic ovary syndrome: a randomized controlled trial. Am J Obstet Gynecol. 2014; 211(5):487.e1-6. doi:10.1016/j.ajog.2014.05.009. Epub 2014 May 9.
15. Marshall K. Polycystic ovary syndrome: clinical considerations. Altern Med Rev. 2001; 6(3):272-92.
16. Marshall JC, Dunaif A. Should all women with PCOS be treated for insulin resistance? Fertil Steril. 2012; 97(1):18-22.
17. Swaroop A, Bagchi M, Kumar P, et al. Safety, efficacy and toxicological evaluation of a novel, patented anti-diabetic extract of Trigonella Foenum-Graecum Seed Extract (Fenfuro). Toxicol Mech Methods. 2014; 24(7):495-503.
18. Lujan ME, Jarrett BY, Brooks ED, et al. Updated ultrasound criteria for polycystic ovary syndrome: reliable thresholds for elevated follicle population and ovarian volume. Hum Reprod. 2013; 28(5):1361-8.
19. Naderpoor N, Shorakee S, de Courten B, et al. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum Reprod Update. 2015; pii dmv025. [Epub ahead of print].
20. He C, Lin Z, Robb SW, et al. Serum Vitamin D Levels and Polycystic Ovary syndrome: A Systematic Review and Meta-Analysis. Nutrients. 2015;7:4555-4577; doi:10.3390/nu7064555.
21. Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 2004; 82:661–5.
22. Dunaif A. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocr Rev. 1997; 18:774–800.
23. Schachter M, Raziel A, Friedler S, et al. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod. 2003; 18:721–7.
24. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001; 111:607–13.
25. Ressler IB, Grayson BE, Ulrich-Lai YM, et al. Diet-induced obesity exacerbates metabolic and behavioral effects of polycystic ovary syndrome in a rodent model. Am J Physiol Endocrinol Metab. 2015; 308(12): 1076-1084.
26. Sarray S, Madan S, Saleh LR, et al. Validity of adiponectin-to-leptin and adiponectin-to-resistin ratios as predictors of polycystic ovary syndrome. Fertil Steril. 2015; doi: 10.1016/j.fertnstert.2015.05.007. [Epub ahead of print].
27. Ezeh U, Pall M, Mathur R, et al. Association of fat to lean mass ratio with metabolic dysfunction in women with polycystic ovary syndrome. Human Reprod. 2014; 29(7):1508-17.
28. Ranasinha S, Joham AE, Norman RJ, et al. The association between polycystic ovary syndrome (PCOS) and metabolic syndrome: A statistical modelling approach. Clin Endocrinol (Oxford). 2015; doi: 10.1111/cen.12830. [Epub ahead of print].
29. Banaszewska B, Spaczynski RZ, Pelesz M, et al. Incidence of elevated LH/FSH ration in polycystic ovary syndrome women with normo-and hyperinsulinemia. Rocz Akad Med Bialymst. 2003; 48:131-4.